Following a full submission
AWMSG advice |
|||
| Status: Not recommended | |||
Buprenorphine (Sixmo®) is not recommended for use within NHS Wales for the substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment. The case for clinical effectiveness and cost-effectiveness has not been proven. |
|||
|
|||
Medicine details |
|||
| Medicine name | buprenorphine (Sixmo®) | ||
| Formulation | 74.2 mg implant | ||
| Reference number | 4262 | ||
| Indication | Substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment |
||
| Company | Accord Healthcare | ||
| BNF chapter | Central nervous system | ||
| Submission type | Full | ||
| Status | Not recommended | ||
| Advice number | 0522 | ||
| NMG meeting date | 05/01/2022 | ||
| AWMSG meeting date | 09/02/2022 | ||
| Date of issue | 23/02/2022 | ||